Notable News Spotlight: Endo International plc (NASDAQ:ENDP)

Endo International plc (NASDAQ:ENDP) spotted trading -87.24% off 52-week high price. On the other end, the stock has been noted 10.28% away from the low price over the last 52-weeks. The stock changed -3.28% to recent value of $2.36. The stock transacted 19601980 shares during most recent day however it has an average volume of 6086.32K shares. The company has 234.98M of outstanding shares and 202.39M shares were floated in the market.  

On Sept. 05, 2019, Endo International plc (NASDAQ:ENDP) declared that its subsidiaries Endo Pharmaceuticals Inc., Endo Health Solutions Inc., Par Pharmaceutical and Par Pharmaceutical Companies (collectively, the Endo Entities) have executed a definitive Settlement Agreement and Release (the Settlement Agreement) with the County of Cuyahoga, Ohio, the County of Summit, Ohio and certain related persons in connection with the following lawsuits pending in the U.S. District Court for the Northern District of Ohio:  The County of Cuyahoga, et al. v. Purdue Pharma, L.P., et al., Case No. 17-OP-45004; and The County of Summit, et al. v. Purdue Pharma, L.P., et al., Case No. 18-OP-45090 (collectively, the Track 1 Cases).  Endo had previously announced a settlement in principle of the Track 1 Cases on August 20, 2019.

The Settlement Agreement fully resolves all claims that were or could have been asserted by the two plaintiff counties against the Endo Entities in the Track 1 Cases, including claims arising from or otherwise relating to the manufacturing, marketing, distribution, supply, sale, prescribing, use and/or abuse of branded and generic opioid medications.  Under the Settlement Agreement, Endo will pay a total sum of $10 million and will provide up to $1 million of its Vasostrict®and Adrenalin® products free of charge, to be initially allocated by and between the two plaintiff counties as follows:  Cuyahoga County will receive $6.2 million in cash and up to $620,000 of Vasostrict® and/or Adrenalin®; and Summit County will receive $3.8 million in cash and up to $380,000 of Vasostrict® and/or Adrenalin®. The two plaintiff counties may further apportion and use the foregoing amounts in their sole discretion.  Further, in the event of a comprehensive resolution of government-related opioid claims, the Company has agreed that the two plaintiff counties will receive the value they would have received under such resolution less the total value of the Settlement Agreement. The Settlement Agreement includes no admission of wrongdoing, fault or liability of any kind by the Endo Entities and avoids litigation risk and associated costs.  It is important to note that the value of the Settlement Agreement should not be extrapolated to any other opioid-related cases or claims.

 Its earnings per share (EPS) expected to touch remained 24.90% for this year while earning per share for the next 5-years is expected to reach at -14.63%. ENDP has a gross margin of 44.90% and an operating margin of 1.10% while its profit margin remained -20.00% for the last 12 months. 

 According to the most recent quarter its current ratio was 1.5 that represents company’s ability to meet its current financial obligations. The price moved ahead of -7.12% from the mean of 20 days, -26.00% from mean of 50 days SMA and performed -67.06% from mean of 200 days price. Company’s performance for the week was -2.07%, 4.89% for month and YTD performance remained -67.67%.

Leave a Reply

Your email address will not be published. Required fields are marked *